Syngene IPO: good for long term investors

Syngene International Ltd (SIL), a subsidiary of Biocon Ltd, is coming out with its maiden IPO via book building process offer for sale from existing stakeholders. It is offering 22000000 equity share of Rs. 10 each in a price band of Rs. 240-250 and thus mulls mobilizing Rs. 528-550 crore on at the basis of lower and upper price band.

Issue opens for subscription on 27.07.15 and will close on 29.07.15. Minimum application is to be made for 60 shares and in multiples thereon, thereafter.



SIL is engaged in contract based discovery, development and manufacturing at its ultra modern world class research and development facility. 95% of its revenue comes from global clients and the rest from domestic clients. As claimed in RHP by promoters and merchant bankers, there are no listed peers to compare with.

Read more at: http://economictimes.indiatimes.com/markets/ipos/fpos/top-five-reasons-why-long-term-investors-should-subscribe-to-syngene-ipo/articleshow/48212739.cms